On January 17, the FDA authorized ZYNs for sale, claiming their benefit to tobacco users outweighed their risk to the public.

A recent study from researchers at Wake Forest University School of Medicine and Rutgers University shows a high rate of ...

Q4 2024 Management View CEO Billy Gifford emphasized the company’s progress in 2024, highlighting a 3.4% growth in adjusted diluted EPS and over $10.2 billion returned to shareholders through ...